Aragen, FAR to advance program in neurodegeneration
Contract Research and Development Organization (CRO) Aragen Life Sciences (Aragen) on Tuesday announced its collaboration with FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company to advance preclinical programmes in neuro-degeneration.
Hyderabad: Contract Research and Development Organization (CRO) Aragen Life Sciences (Aragen) on Tuesday announced its collaboration with FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company to advance preclinical programmes in neuro-degeneration.
As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule programme.
“We look forward to initiating our collaboration with FAR Biotech to advance its pipeline of therapeutic candidates,” said Dr Ramesh Subramanian, Chief Commercial Officer, Aragen. “Aragen has developed strong capabilities in providing integrated drug discovery (IDD) solutions to its customers to accelerate their discovery programmes and this collaboration marks an inflection point for our IDD vertical.”
Hyderabad-based Aragen operates through a global network of six sites with a team of over 4,200 employees and 450 PhDs. Its expertise and experience have enabled over 450 customers in advancing their research programmes from early discovery through development and commercialisation.
